Taken together, these results indicate that although third-generation costimulatory CD19 CAR-modified T cells efficiently eliminated CD19+ tumor cells in vivo, the limited lifespan significantly limited the therapeutic effects of CAR T cells. This evidence concerns the gene CD19 and neoplasm.